TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15116862

Group type: EXPERIMENTAL
Intervention: Transtelephonic event recorder (TER)
Number of subjects: 310

Group type: COMPARATOR
Intervention: 24-hour Holter monitoring
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of TER
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Time to diagnosis with TER
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 310
Study: 11126938

Group type: EXPERIMENTAL
Intervention: Recognition judgments with instructions conforming to those reported by Jacoby (1991)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fame judgments in the process dissociation procedure
Number of subjects: 0
Study: 8996011

Group type: EXPERIMENTAL
Intervention: Nasal oxygen therapy
Number of subjects: 20
Study: 8370131

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg administered at 1600 and 2000 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 7
Study: 3529744

Group type: EXPERIMENTAL
Intervention: Plasmaexchange (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Drug therapy only (group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Plasmaexchange therapy
Number of subjects: 44
Study: 31678222

Group type: EXPERIMENTAL
Intervention: Robot-assisted arm therapy and hand functional electrical stimulation (RAT+FES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intensive conventional therapy
Number of subjects: 40
Study: 28872259

Group type: EXPERIMENTAL
Intervention: Precipitating factors identified at admission (CV, non-CV, unknown)
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Precipitating factors identified at admission (arrhythmia, respiratory infection, other non-CV factors)
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Precipitating factors (CV, non-CV, unknown)
Number of subjects: 1668
Study: 26796630

Group type: EXPERIMENTAL
Intervention: Bilateral Cochlear Implantation (BCI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unilateral Cochlear Implantation (UCI)
Number of subjects: 38
Study: 24291283

Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Transfemoral Transcatheter Aortic Valve Replacement (TF-TAVR)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Transapical Transcatheter Aortic Valve Replacement (TA-TAVR)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Major bleeding complications (BC)
Number of subjects: 657
Study: 22894640

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (640 mg t.i.d during chemotherapy with paclitaxel and one month after)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 57
Study: 20865998

Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention
Number of subjects: 0
Study: 18540800

Group type: EXPERIMENTAL
Intervention: Psychoeducation workshop
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 50
Study: 16371893

Group type: EXPERIMENTAL
Intervention: Spine clinic intervention (medical examination, information, reassurance, encouragement to engage in physical activity)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Spine clinic intervention
Number of subjects: 457

Group type: COMPARATOR
Intervention: Usual primary healthcare treatment
Number of subjects: 457
Study: 12208703

Group type: EXPERIMENTAL
Intervention: Argon laser peripheral iridoplasty (ALPI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional systemic medical therapy
Number of subjects: 64
Study: 10342702

Group type: EXPERIMENTAL
Intervention: Two doses of measles vaccine at 6 and 9 months
Number of subjects: 2181

Group type: COMPARATOR
Intervention: One dose of inactivated polio vaccine (IPV) at 6 months and measles vaccine at 9 months
Number of subjects: 2181
Study: 8676932

Group type: COMPARATOR
Intervention: Rifabutin (300 mg daily)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Azithromycin (1200 mg weekly)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Both drugs (Rifabutin and Azithromycin)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 693
Study: 1886824

Group type: EXPERIMENTAL
Intervention: Scotchbond (3M Dental Products, St. Paul, MN) - etched
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scotchbond (3M Dental Products, St. Paul, MN) - unetched
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scotchbond 2 (3M Dental Products, St. Paul, MN) - etched
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scotchbond 2 (3M Dental Products, St. Paul, MN) - unetched
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gluma (Bayer Dental, Leverkusen, Federal Republic of Germany) - etched
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gluma (Bayer Dental, Leverkusen, Federal Republic of Germany) - unetched
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bondlite (Kerr Manufacturing Co., Romulus, MI) - etched
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bondlite (Kerr Manufacturing Co., Romulus, MI) - unetched
Number of subjects: 40
Study: 6175137

Group type: EXPERIMENTAL
Intervention: Active transfer factor (TF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Heat-inactivated transfer factor (placebo)
Number of subjects: 16
Study: 30531420

Group type: EXPERIMENTAL
Intervention: PASCAL PRP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laser PRP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (PASCAL and Conventional)
Number of subjects: 0
Study: 31808921

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Standard Care Control (SCC)
Number of subjects: 339
Study: 28186425

Group type: EXPERIMENTAL
Intervention: IM tramadol/propofol fast (GIMF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: IM tramadol/propofol slow (GIMS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral tramadol/propofol fast (GOF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral tramadol/propofol slow (GOS)
Number of subjects: 24
Study: 26122425

Group type: EXPERIMENTAL
Intervention: 1,470-nm endovenous laser ablation (EVLA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 120
Study: 23557881

Group type: EXPERIMENTAL
Intervention: High-normal proficiency group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-normal proficiency group
Number of subjects: 30
Study: 22009806

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic prophylaxis administered before TUL
Number of subjects: 114

Group type: COMPARATOR
Intervention: TUL without antibiotic prophylaxis
Number of subjects: 114
Study: 19571807

Group type: EXPERIMENTAL
Intervention: CYP2C9 and VKORC1 genotype-guided dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard dosing without genotype guidance)
Number of subjects: 0
Study: 15878727

Group type: EXPERIMENTAL
Intervention: Focal basal ganglia lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients with focal lesions of other brain structures)
Number of subjects: 0
Study: 12209278

Group type: COMPARATOR
Intervention: Labetalol (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nicardipine (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 60
Study: 10509499

Group type: EXPERIMENTAL
Intervention: Multidisciplinary, home-based intervention (home visit by a cardiac nurse 7-14 days after discharge)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multidisciplinary, home-based intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 8733499

Group type: EXPERIMENTAL
Intervention: Nebulised acetylcysteine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulised normal saline
Number of subjects: 10
Study: 1926232

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (surgery)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Medical therapy (acetylsalicylic acid and dipyridamole)
Number of subjects: 410
Study: 6861867

Group type: EXPERIMENTAL
Intervention: Sotalol 100 mg intravenously
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sotalol 400 mg orally
Number of subjects: 6
Study: 30879998

Group type: EXPERIMENTAL
Intervention: 0.37 μg of Alt a 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 μg of Alt a 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28739973

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (cLA) coadministered with 15NO2‐
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15NO2‐
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15NO3‐ and 15NO2‐
Number of subjects: 0
Study: 26111165

Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (12 weeks)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study: 24780066

Group type: EXPERIMENTAL
Intervention: Low-dose glucose (0.1 g/kg/h for 1 h followed by 0.05 g/kg/h for 1 h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No glucose (0G group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose glucose (LG group)
Number of subjects: 34
Study: 23062390

Group type: EXPERIMENTAL
Intervention: Preseasonal grass pollen immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19453867

Group type: EXPERIMENTAL
Intervention: Oral health education program (4-month duration)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 247
Study: 17949398

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Both CQ and SP
Number of subjects: 653
Study: 15898864

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for insomnia during discontinuation
Number of subjects: 52

Group type: COMPARATOR
Intervention: No cognitive-behavior therapy for insomnia during discontinuation
Number of subjects: 52
Study: 12471781

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine with clonidine 2 micrograms.kg‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 45
Study: 9819068

Group type: EXPERIMENTAL
Intervention: Cortisol 40 mg/d
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cortisol 160 mg/d
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7543407

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan (L-5-HTP) plus carbidopa
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L-5-HTP
Number of subjects: 6
Study: 2694344

Group type: EXPERIMENTAL
Intervention: Furazolidone (5 mg/kg/day for 5 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ampicillin (100 mg/kg/day for 5 days)
Number of subjects: 78
Study: 331465

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 6
Study: 30724351

Group type: EXPERIMENTAL
Intervention: Hurley staging in the axillae
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hurley staging in the gluteal region
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hurley staging in the groin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Physician's Global Assessment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Refined Hurley staging
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: International HS Severity Scoring System
Number of subjects: 24
Study: 29186247

Group type: EXPERIMENTAL
Intervention: OFI-ALA-PDT (optical intra-tissue fiber irradiation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Traditional ALA-PDT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OFI (optical fiber irradiation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Blank control group (no treatment)
Number of subjects: 25
Study: 26681020

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel (test preparation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 75 mg clopidogrel (reference preparation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Relative bioavailability of the test preparation
Number of subjects: 32
Study: 23059649

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 4000 IU/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 7000 IU/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Baseline serum 25D <50.0 nmol/L in 50% of subjects
Number of subjects: 44
Study: 22136021

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Jiaji (EX-B 2), Shenshu (BL 23), Qihaishu (BL 24), Guanyuanshu (BL 26), Dachangshu (BL 25), Yangtlingquan (GB 34) once a day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Oral administration of Fugui Gutong capsule (3 times a day, 4 capsules each time) and 0.3 g ibuprofen (once a day)
Number of subjects: 85
Study: 19593890

Group type: EXPERIMENTAL
Intervention: Low-dose adenosine infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study: 15899453

Group type: EXPERIMENTAL
Intervention: Cataract surgery with anterior vitrectomy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cataract surgery without anterior vitrectomy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cataract surgery for after-cataract
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cataract surgery with AcrySof SA30AL IOL
Number of subjects: 66
Study: 12214948

Group type: EXPERIMENTAL
Intervention: Colgate Platinum
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Starbrite
Number of subjects: 24
Study: 9456291

Group type: EXPERIMENTAL
Intervention: Nifedipine capsules (10 mg, two administrations 6 hours apart)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nifedipine-retard (20 mg tablets, single administration)
Number of subjects: 21
Study: 8546978

Group type: EXPERIMENTAL
Intervention: Clinical handbook for continence care
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no handbook)
Number of subjects: 124
Study: 2576717

Group type: EXPERIMENTAL
Intervention: Vecuronium 'priming' group (10 micrograms.kg‐1 followed by 100 micrograms.kg‐1 4 min later)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Vecuronium 'control' group (100 micrograms.kg‐1)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Vecuronium 'high dose' group (250 micrograms.kg‐1)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Succinylcholine group (1 mg.kg‐1)
Number of subjects: 340
Study: 16041

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 15 mg flurazepam
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 28405814

Group type: EXPERIMENTAL
Intervention: Virgin coconut oil (VCO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (extra-virgin olive oil)
Number of subjects: 15
Study: 27633643

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC): a manualised consultation with a child and adolescent psychiatrist and individualised treatment plan
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group-based Acceptance and Commitment Therapy (ACT) plus Enhanced Usual Care (EUC)
Number of subjects: 120
Study: 24739659

Group type: EXPERIMENTAL
Intervention: Intensive and multidisciplinary program conducted in a rehabilitation center
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Less intensive outpatient program conducted by a private physiotherapist
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mixed strategy combining outpatient program with a multidisciplinary intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mixed strategy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Intensive and multidisciplinary program
Number of subjects: 180

Group type: COMPARATOR
Intervention: Less intensive outpatient program
Number of subjects: 180
Study: 22105505

Group type: EXPERIMENTAL
Intervention: Heidelberg retinal tomography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 30
Study: 20831989

Group type: EXPERIMENTAL
Intervention: Batroxobin (5 IU through intravenous drip once every alternate day for a total of six doses)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Aspirin (control group)
Number of subjects: 52
Study: 18410301

Group type: EXPERIMENTAL
Intervention: Women with sexual arousal disorder (29 participants)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Women without sexual problems (30 participants)
Number of subjects: 59
Study: 16309036

Group type: EXPERIMENTAL
Intervention: Ketoconazol 400 mg + Clindamycin 100 mg for 6 days (K/C6D)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Ketoconazol 800 mg + Clindamycin 100 mg for 3 days + placebo for 3 days (K/C3D)
Number of subjects: 82
Study: 11868797

Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide combination (80 mg valsartan o.d. for 4 weeks, then fixed combination if needed)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg o.d. for 4 weeks, then increased to 10 mg if needed)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Both regimens (valsartan/hydrochlorothiazide and amlodipine)
Number of subjects: 310
Study: 9728901

Group type: EXPERIMENTAL
Intervention: Combined contraceptive pill (250 microg levonorgestrel plus 30 microg ethinyl estradiol) administered intravaginally, one tablet per week for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conjugated estrogen cream (0.625 mg conjugated equine estrogens) administered intravaginally, 1 gm at bedtime, three times in the first week, twice in the second week, and then once a week for the next 6 weeks
Number of subjects: 40
Study: 7639971

Group type: EXPERIMENTAL
Intervention: Low dose didanosine (200 mg for bodyweight < 60 kg; 134 mg for bodyweight ≥ 60 kg)
Number of subjects: 426

Group type: COMPARATOR
Intervention: High dose didanosine (750 mg for bodyweight ≥ 60 kg; 500 mg for bodyweight < 60 kg)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Both low and high dose didanosine
Number of subjects: 426
Study: 2768496

Group type: EXPERIMENTAL
Intervention: MMPI under standard conditions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fake good response set (MMPI for job application)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fake bad response set (qualify for psychotherapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conversion of raw scores to T scores
Number of subjects: 40
Study: 951455

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise on a treadmill at 40 degrees or 10 degrees C
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Familial studies (monozygotic twins)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Familial studies (dizygotic twins)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Same-sex siblings discordant for affective illness
Number of subjects: 15
Study: 30668163

Group type: EXPERIMENTAL
Intervention: Complior
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Arteriograph
Number of subjects: 316
Study: 28053896

Group type: EXPERIMENTAL
Intervention: Champignon extract 50 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Champignon extract 500 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Champignon extract 1000 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25565656

Group type: EXPERIMENTAL
Intervention: 100 mg of intravenous hydrocortisone 2 hours prior to surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 23493410

Group type: EXPERIMENTAL
Intervention: Systematic CRT optimization (at implant, at 3 and 6 months)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Non-systematic CRT optimization (less than three times during the year)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Systematic CRT optimization
Number of subjects: 199

Group type: COMPARATOR
Intervention: Non-systematic CRT optimization
Number of subjects: 199
Study: 21932302

Group type: EXPERIMENTAL
Intervention: preHD group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 19555590

Group type: EXPERIMENTAL
Intervention: HV training with cognitive behavioural approach (CBA)
Number of subjects: 4084

Group type: EXPERIMENTAL
Intervention: HV training with person-centred approach (PCA)
Number of subjects: 4084

Group type: EXPERIMENTAL
Intervention: HV training (combined intervention group)
Number of subjects: 4084

Group type: COMPARATOR
Intervention: Control group (HV usual care)
Number of subjects: 4084

Group type: EXPERIMENTAL
Intervention: Intervention group (HV training)
Number of subjects: 4084
Study: 17182977

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HOE‐140 (18 μg/kg/h i.v. for 6 h)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HOE‐140
Number of subjects: 25
Study: 15333192

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Central laboratory testing (CLT)
Number of subjects: 263
Study: 11489570

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% twice a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% twice a day and dorzolamide 2% 3 times a day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dorzolamide 2% 3 times a day
Number of subjects: 45
Study: 9682660

Group type: EXPERIMENTAL
Intervention: High-MUFA meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medium-MUFA meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-MUFA meal
Number of subjects: 30
Study: 7973963

Group type: EXPERIMENTAL
Intervention: Lateral decubitus position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 50